Raymond James Forecasts Strong Price Appreciation for HLS Therapeutics (TSE:HLS) Stock

HLS Therapeutics (TSE:HLS) had its price objective hoisted by analysts at Raymond James from C$4.00 to C$5.00 in a research note issued to investors on Friday,BayStreet.CA reports. Raymond James’ price target would indicate a potential upside of 42.86% from the stock’s current price.

Separately, Stifel Nicolaus lowered their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.

HLS Therapeutics Stock Performance

Shares of TSE:HLS traded up C$0.19 during trading on Friday, hitting C$3.50. 7,061 shares of the company traded hands, compared to its average volume of 26,986. HLS Therapeutics has a one year low of C$3.00 and a one year high of C$5.48. The company has a quick ratio of 1.01, a current ratio of 2.02 and a debt-to-equity ratio of 100.44. The business’s fifty day moving average is C$3.54 and its 200-day moving average is C$3.51. The stock has a market capitalization of C$111.27 million, a price-to-earnings ratio of -3.47 and a beta of 1.07.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.